New Zealand's controversial medicines purchasing agency Pharmac has announced that it will fund MSD's KEYTRUDA (pembrolizumab) and Roche's TECENTRIQ (atezolizumab) for people with locally advanced and metastatic non-small cell lung cancer. …
The long wait is finally over for New Zealand's lung cancer patients
March 13, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
Ombudsman's 'State of the Health Funds Report' confirms a decline in complaints
March 20, 2023 - - Other Health -
Aurora Healthcare and Medibank partner to boost access to mental health care
March 20, 2023 - - Other Health -
Bupa puts First Nations Health at the centre of Reconciliation Action Plan
March 20, 2023 - - Latest News -
Monash University in new partnership with leading Israeli research hospital
March 20, 2023 - - Australian Biotech -
Australian company Clinuvel initiates second trial of new anti-stroke candidate
March 20, 2023 - - Australian Biotech -
Organon partners with foundation to relaunch 'No Limits 4 Girls' program
March 20, 2023 - - Latest News -
Moderna officially launches Australian mRNA fellowship program
March 20, 2023 - - Latest News